

## Primary Care Network Bulletin: April 2022

### Included in this Bulletin:

- GM Study Day – 26<sup>th</sup> April 2022
- GatewayC Live GM Infographics & Webinars
- Prostate Risk Animation
- Rapid Diagnostic Centre: roll-out update
- Answer Cancer: Training
- NHSE/I Cytosponge Pilot in GM
- Future sessions & Future Topics
- Coming soon...

### Prostate Cancer Animation: Know the Risks

Prostate cancer is the most common form of cancer for men in the UK. This animation has been developed to educate and inform men who may be at a higher risk of developing prostate cancer.

Prostate Cancer: Know the Risks:

<https://www.youtube.com/watch?v=PeEmzGcedHY>

Please encourage practices in your PCN to share this link with their patients as appropriate and via practice websites.



**Rapid Diagnostic Centre (RDC): roll-out update: Rapid Diagnostic Centres are now live in every locality across Greater Manchester.**

RDCs introduce a new non-specific symptom pathway for patients who display symptoms that could indicate cancer that don't align to a site specific cancer - such as unexplained weight loss, fatigue or vague abdominal pain. The new non-specific pathway complements current cancer diagnostic pathways and makes sure everyone with non-site specific or vague symptoms get the right tests at the right time in as few visits as possible.

The Non-Specific Symptoms Suspected Cancer referral form is now available on all primary care systems.

RDCs focus on 7 Faster Diagnosis Principles outlined in the attached slide deck



### GM Study Day 26<sup>th</sup> April 2022:

We have an in-person event taking place in April.

The event is suitable for **all primary care professionals** across Greater Manchester.

The places are fully funded and there will be a complimentary lunch for all delegates attending in person.

Join Greater Manchester Cancer Alliance and GatewayC on **Tuesday 26<sup>th</sup> April** for this study afternoon which will be filled with discussions from leading cancer specialists. Each session will refresh your cancer knowledge, enable you to hear the latest pathway information, and include a live Q&A.

Confirmed cancer topics include:

- Colorectal
- Pancreatic
- Non-site-specific
- Ovarian
- Lung

Attendees will be able to **access the study afternoon via live-stream or in-person**. This event is part of a shared commitment to improve the proportion of cancers diagnosed at an early stage, support faster diagnosis, and improve patient experiences of the referral process.

To register for your free place, please visit [bit.ly/3Hs6GQ5](https://bit.ly/3Hs6GQ5)



### GatewayC Live Greater Manchester: Infographics and Webinars

Please see the link below to all the GatewayC Live GM webinar materials produced to date: <https://www.gatewayc.org.uk/free-webinars-gm/>

Hard copies of the infographics will be sent out to each practice following the GM Study Day on the 26<sup>th</sup> April.

We have commissioned a further roll-out of GatewayC Live GM Webinars for 22/23 – **if there are any specific topics you would like us to cover, please get in touch and let us know!**

### ANSWER CANCER

**Free online training sessions from Answer Cancer, the Greater Manchester Cancer Screening Engagement Programme.**

Please see attached information from Answer Cancer and links to register for the training sessions scheduled throughout **April; May and June**.

### NHSE/I Cytosponge Pilot in GM:

In January 2021 NHSE/I launched a trial pilot of Cytosponge across the country including 3 Trusts in Greater Manchester: **Salford; Oldham & Leigh**.

This is a new diagnostic test that detects early Oesophageal cell changes (dysplasia) in patients with reflux symptoms and in Barrett's surveillance patients. Early detection of cell changes (dysplasia) can make treatment much easier and successful, identifying these cell changes through screening is important to ensure conditions such as Barrett's do not progress to become oesophageal cancer.

The Cytosponge is a small capsule which is attached to a fine string. After swallowing, the capsule coating (vegetarian gelatine) dissolves in the stomach to release a small brush or sponge which when removed allows cell collection from the lining of the oesophagus. These cells are then analysed for abnormalities. The test itself takes around 15 minutes and has been found in several studies to be safe, well-tolerated and effective.

Another key benefit to Cytosponge is that it also enables releasing capacity in stretched endoscopy units, especially following Covid, so that all patients can be prioritised effectively to support a reduction in waiting lists. The pilot is now in the evaluation phase for the first year which includes clinical and patient feedback.

NHSE/I have now confirmed that the pilot will continue in 2022/23 in the same Trusts.

### Future PCN Cancer Lead Sessions & dates for your calendars:



Tuesday 24<sup>th</sup> May 2022 (1-2pm) – Cervical Cancer & Screening

Tuesday 28<sup>th</sup> June 2022 (1-2pm) – Dermatology / Teledermatology

Tuesday 26<sup>th</sup> July 2022 (1-2pm)

Tuesday 30<sup>th</sup> August 2022 (1-2pm)

Tuesday 27<sup>th</sup> September 2022 (1-2pm)

Tuesday 25<sup>th</sup> October 2022 (1-2pm)

Tuesday 29<sup>th</sup> November 2022 (1-2pm)

Tuesday 31<sup>st</sup> January 2023 (1-2pm)

Tuesday 28<sup>th</sup> February 2023 (1-2pm)

Tuesday 28<sup>th</sup> March 2023 (1-2pm)

### Coming soon....

- ✓ Translated 2ww referral letters for patients
- ✓ Translated FIT Patient Information Leaflets
- ✓ Non-Site Specific infographic & Fast Facts video
- ✓ Bowel Symptom Animation
- ✓ BI Data Session



Any feedback or queries please direct to:

[Rebecca.Davies89@nhs.net](mailto:Rebecca.Davies89@nhs.net); [Alison.Jones8@nhs.net](mailto:Alison.Jones8@nhs.net); [SLTaylor@nhs.net](mailto:SLTaylor@nhs.net)

